#USA #Duluth #VitaSmart #Bridge to Life #HOPE Perfusion

A Revolutionary Advance in Organ Preservation

A recent landmark study published in the Journal of the American Medical Association (JAMA) Surgery has confirmed the VitaSmart™ HOPE Perfusion System developed by Bridge to Life™ Ltd. as a groundbreaking technology in organ preservation. With the increase in donor organ shortages, this innovative system promises to unlock new opportunities for organ transplantation, significantly enhancing the availability of organs for the over 100,000 patients currently awaiting transplants in the United States.

The Study: Key Insights

The study, known as Bridge to HOPE, is the first multicenter, randomized trial in the U.S. specifically evaluating the clinical impact of hypothermic oxygenated perfusion (HOPE) on high-risk liver transplants. Conducted across 15 transplant centers, the trial enrolled 219 organ recipients, focusing on those receiving organs from high-risk, extended criteria donors. These include both Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) grafts.

The results of the trial were remarkable. The utilization of the VitaSmart™ HOPE System resulted in statistically significant improvements in organ utilization and post-transplant outcomes among recipients. This technique not only showcased the safety and efficacy of hypothermic oxygenated perfusion but also demonstrated its potential to expand the use of marginal donor organs, further alleviating the burden of organ shortages

Clinical Benefits and Opportunities

Mauricio Carvalho, VP of Medical Affairs at Bridge to Life Ltd., expressed that the results of the study present a transformative opportunity for the transplant community. The findings underscored how portal venous HOPE could be a simple, safe, and highly effective preservation strategy, with significant clinical benefits compared to traditional storage methods. It offers practical logistic viability as an alternative to normothermic machine perfusion, which is limited by existing infrastructure in the U.S.

Moreover, the overall liver-related complications observed in trial participants were notably reduced, solidifying the HOPE approach as not just a superior preservation technology, but also a fundamentally different methodology that can lead to better patient outcomes.

A Vision for the Future

Don Webber, CEO and President of Bridge to Life, highlighted the importance of this study's publication and its implications for both surgical practices and patients awaiting organ transplants. He emphasized the company's commitment to overcoming the operational and logistical challenges that have caused underutilization of perfusion techniques in the U.S., which traditionally hinder the number of livers that can be successfully transplanted.

“Bridge to Life is focusing on removing these constraints,” he explained, “by providing solutions that can be easily integrated into existing transplant workflows. Our goal is to facilitate broader adoption of this innovative technology, ensuring that thousands of patients have a better shot at receiving the organ transplants they desperately need.”

About Bridge to Life Ltd.

Bridge to Life Ltd. has established itself as a leader in organ preservation solutions, with a commitment to quality, innovation, and accessibility. Their suite of products, including the VitaSmart™ Hypothermic Oxygenated Perfusion System, plays a pivotal role in the global organ transplantation landscape. By partnering with leading transplant centers and organ procurement organizations, the company aims to positively impact the future of organ transplantation and improve the lives of countless individuals awaiting a second chance at life.

In conclusion, the validation of the VitaSmart HOPE Perfusion System signifies not only an evolution in the field of organ preservation but also a beacon of hope for patients awaiting transplants. By addressing the constraints of the current systems, Bridge to Life is opening up new avenues to enhance organ utilization, ultimately leading to better outcomes for patients across the nation.